Trial Profile
CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Low molecular weight heparins
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 28 Apr 2021 According to clinicaltrials.gov the study was discontinued as a result of low recruitment.
- 28 Apr 2021 Status changed from suspended to discontinued.
- 23 Jul 2019 Status changed from recruiting to suspended.